phase 3 trial – Medxy AI

Sibeprenlimab Demonstrates Kidney Function Preservation in IgA Nephropathy: Insights from the Final Phase 3 VISIONARY Trial

By MedXY 10/30/2026

The phase 3 VISIONARY trial establishes sibeprenlimab as a promising therapy in IgA nephropathy, significantly stabilizing eGFR decline and reducing kidney-function deterioration over 24 months with a favorable safety profile.

Clinical Updates Nephrology

Ravulizumab in IgA Nephropathy: Interim Phase 3 Trial Analysis and Translational Insights

By MedXY 10/30/2026

Ravulizumab, a terminal complement C5 inhibitor, significantly reduces proteinuria in adults with IgA nephropathy, demonstrating safety and biomarker improvements in phase 2 and 3 trials, highlighting its therapeutic potential.

Clinical Updates news

Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial Review

By MedXY 09/06/2026

This review synthesizes evidence from a phase 3 trial demonstrating improved pathological complete response rates with neoadjuvant anbenitamab and HB1801 in ERBB2-positive breast cancer, highlighting efficacy, safety, and clinical implications.

Diabetes & Endocrinology news Ophthalmology

Veligrotug Delivers Rapid, Durable Benefit in Active Thyroid Eye Disease in the Phase 3 THRIVE Trial

By MedXY 06/06/2026

In phase 3 testing, veligrotug produced rapid and clinically meaningful reductions in proptosis, diplopia, and disease activity in active thyroid eye disease, with durable benefit through 52 weeks and a favorable short-term safety profile.

Gastroenterology news Oncology

Intraperitoneal and Intravenous Paclitaxel Plus S-1 Improves Survival in Gastric Cancer With Peritoneal Metastasis: Phase 3 Trial

By MedXY 05/25/2026

A phase 3 trial found that adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improved survival in gastric cancer with peritoneal metastasis without increasing severe toxicity.

Cardiology news

Rationale and Design of CARDIO-TTRansform: A Phase 3 Trial of Eplontersen for Transthyretin Amyloid Cardiomyopathy

By MedXY 05/10/2026

CARDIO-TTRansform is a global Phase 3 trial evaluating eplontersen's efficacy and safety in reducing cardiovascular events in transthyretin amyloid cardiomyopathy patients receiving standard care, including TTR stabilizers. With 1,432 participants, it aims to establish a new treatment paradigm.

Infectious Diseases news Pediatrics

EuTCV Vi‑CRM197 (Single‑ and Multidose) Is Non‑Inferior to Typbar TCV in Infants and Well Tolerated Across Age Groups in Kenya and Senegal

By MedXY 11/30/2025

A multicentre phase 3 trial shows single‑ and multidose EuTCV (Vi‑CRM197) are immunologically non‑inferior to Typbar TCV in infants 9–12 months, with comparable safety and reactogenicity across ages — supporting WHO prequalification.

Oncology Respiratory

Advancing First-Line Treatment in Metastatic NSCLC: The Promise of Retifanlimab Combined with Chemotherapy

By MedXY 10/17/2025

This article reviews the phase 3 POD1UM-304 trial demonstrating that adding retifanlimab to platinum-based chemotherapy improves overall survival in first-line metastatic NSCLC, highlighting its potential as a new standard of care.

Hematology-Oncology news Oncology Specialties

Optimizing Treatment in Frail Elderly with Newly Diagnosed Multiple Myeloma: Insights from the IFM2017-03 Trial on Dexamethasone-Sparing Daratumumab and Lenalidomide Regimen

By MedXY 10/15/2025

The IFM2017-03 phase 3 trial demonstrates that a dexamethasone-sparing regimen combining daratumumab with lenalidomide markedly improves progression-free survival in frail elderly multiple myeloma patients, without increasing serious adverse events.

Diabetes & Endocrinology Specialties

Efficacy and Safety of Ecnoglutide, a cAMP-Biased GLP-1 Receptor Agonist, in Weight Management for Overweight and Obese Adults: Insights from a Phase 3 Multicentre Randomised Trial

By MedXY 08/27/2025

This review synthesizes evidence from a multicentre, phase 3 trial on ecnoglutide, demonstrating significant and sustained weight loss in overweight/obese adults without diabetes, with a favorable safety profile, supporting its clinical use in weight management.

Oncology Radiology Specialties

Comparative Efficacy of Induction-Concurrent Versus Concurrent-Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial

By MedXY 08/23/2025

A phase 3 trial showed no significant difference in 3-year progression-free survival between induction-concurrent and concurrent-adjuvant chemoradiotherapy in treating high-risk N2-N3 nasopharyngeal carcinoma, with both regimens exhibiting manageable safety profiles.

Clinical Updates news Oncology Specialties

Selumetinib for Adults with NF1-Associated Inoperable Plexiform Neurofibromas: Results from the KOMET Phase 3 Trial

By MedXY 08/03/2025

The KOMET phase 3 trial shows selumetinib offers significant tumor response in adults with NF1 and inoperable plexiform neurofibromas, with a manageable safety profile.

Clinical Updates Hematology-Oncology news Specialties

Mitapivat Offers New Hope for Adults with Non-Transfusion-Dependent α- and β-Thalassaemia: Results from the Phase 3 ENERGIZE Trial

By MedXY 08/02/2025

Mitapivat significantly improves haemoglobin levels in adults with non-transfusion-dependent α- or β-thalassaemia, offering a promising oral therapeutic option with manageable safety profile.

Clinical Updates Diabetes & Endocrinology news Specialties

Inebilizumab for Generalized Myasthenia Gravis: Results from a Phase 3 Randomized Trial

By MedXY 08/01/2025

A phase 3 trial shows inebilizumab, a CD19+ B-cell depleting antibody, improves function and reduces disease severity in generalized myasthenia gravis without increasing serious adverse events.

Clinical Updates news Oncology Specialties

Tarlatamab versus Chemotherapy in Relapsed Small-Cell Lung Cancer: Results from the Phase 3 DeLLphi-304 Trial

By MedXY 07/31/2025

Tarlatamab significantly improves overall survival and reduces severe adverse events compared to chemotherapy in patients with small-cell lung cancer progressing after platinum-based therapy.